Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.

[1]  K. Mahaffey,et al.  Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. , 2020, Kidney international.

[2]  P. Dandona,et al.  Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. , 2020, The Journal of clinical endocrinology and metabolism.

[3]  M. Woodward,et al.  Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. , 2020, JACC. Heart failure.

[4]  T. Maruyama,et al.  Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease , 2019, Diabetes technology & therapeutics.

[5]  Lawrence A Leiter,et al.  Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease. , 2019, Circulation.

[6]  F. Geurts,et al.  The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. , 2019, Kidney international.

[7]  L. Szczech,et al.  Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. , 2019, The New England journal of medicine.

[8]  G. Laverman,et al.  Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors , 2019, Journal of Clinical Medicine.

[9]  S. Goto,et al.  Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. , 2019, Circulation.

[10]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[11]  M. Fudim,et al.  Calculated Estimates of Plasma Volume in Patients With Chronic Heart Failure-Comparison With Measured Volumes. , 2018, Journal of cardiac failure.

[12]  S. Fishbane,et al.  Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  B. Zinman,et al.  How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[14]  D. Maric,et al.  Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia , 2017, Science Translational Medicine.

[15]  J. Wish,et al.  Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  E. Ferrannini,et al.  Renal Handling of Ketones in Response to Sodium–Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes , 2017, Diabetes Care.

[17]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[18]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[19]  J. Cohn,et al.  Calculated plasma volume status and prognosis in chronic heart failure , 2015, European journal of heart failure.

[20]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[21]  I. Macdougall,et al.  The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[23]  A. Webster,et al.  Parenteral versus oral iron therapy for adults and children with chronic kidney disease. , 2012, The Cochrane database of systematic reviews.

[24]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[25]  Uzma F Mehdi,et al.  Anemia, Diabetes, and Chronic Kidney Disease , 2009, Diabetes Care.

[26]  G. Bakris,et al.  Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. , 2005, Kidney international.

[27]  J. Daugirdas,et al.  Handbook of Dialysis , 1988 .